Psychedelics for PTSD: Veterans, advocates seek to make the' long, strange trip' a bit shorter

WKYC Channel 3
6 Jun 202303:40

Summary

TLDRVeteran John Lebecki, who suffered from PTSD and multiple suicide attempts, found relief in an unlikely place: a clinical trial using MDMA, also known as ecstasy. The trial, part of the Multidisciplinary Association for Psychedelic Studies (MAPS), reported significant symptom reduction for 88% of participants and a 'cure' for 67%. While awaiting FDA approval for MDMA as a treatment, Lebecki advocates for veteran access to psychedelics and supports civilians in Ukraine. The story highlights the potential of psychedelic substances in mental health treatment, with ongoing trials for LSD and psilocybin in Ohio.

Takeaways

  • 🌟 A veteran named John Lebecki, who served in the Marine Corps and U.S. Army, struggled with PTSD after his deployments.
  • ⚠ The story contains a discussion of suicide, which may be triggering for some individuals.
  • 💊 The FDA has granted fast track status to two psychedelic substances for their potential benefits in treating mental health issues.
  • 🌈 John Lebecki tried cannabis and was prescribed 42 pills a day by the VA, but these did not prevent his fifth suicide attempt.
  • 💊 He later participated in a clinical trial using MDMA (known as Molly or Ecstasy) for PTSD, which showed significant promise.
  • 🧠 MDMA is not a cure but a tool that, when combined with intensive therapy, helps patients process traumatic memories.
  • 🔍 The Multidisciplinary Association for Psychedelic Studies (MAPS) reported 88% of participants with severe PTSD had significant symptom reduction, and 67% were essentially cured.
  • đŸ„ MAPS will request FDA approval for MDMA once their final report is released, possibly as early as October.
  • 🛑 Despite potential FDA approval, MDMA will not be immediately available due to a lack of trained providers to administer the drug and manage patient reactions.
  • đŸ—Łïž John Lebecki advocates for veteran access to psychedelics and educates in Ukraine, emphasizing the importance of hope in mental health recovery.

Q & A

  • What is the main topic of the video script?

    -The main topic of the video script is the use of psychedelic substances, specifically MDMA, as a potential treatment for Post-Traumatic Stress Disorder (PTSD) in veterans.

  • What is the FDA's current stance on the use of psychedelic substances for mental health issues?

    -The FDA has given fast track status to two psychedelic substances after they showed benefits for those battling mental health issues and there is a chance one may get approval by the end of the year.

  • Who is the veteran featured in the story, and what branch of the military did he serve in?

    -The veteran featured in the story is John Lebecki, who served in both the Marine Corps and the U.S. Army between 1995 and 2009.

  • What percentage of deployed service members are affected by PTSD according to the script?

    -According to the script, roughly 16% of deployed service members are affected by PTSD.

  • What was John Lebecki's experience with the traditional treatment offered by the VA?

    -John Lebecki was on 42 pills a day as part of his treatment by the VA, but it did not prevent his fifth and final suicide attempt.

  • What alternative treatment did John Lebecki explore for his PTSD?

    -John Lebecki explored the use of MDMA, also known as Molly or Ecstasy, as an alternative treatment for his PTSD.

  • How does MDMA function as part of the treatment for PTSD according to the script?

    -MDMA is described as a tool that puts the mind, body, and spirit in the place it needs to be for therapy to work, rather than fixing anything on its own.

  • What organization conducted the study that John Lebecki participated in?

    -John Lebecki participated in a study conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS).

  • What were the reported outcomes of the MAPS study on MDMA for PTSD?

    -The MAPS study reported that 88% of those with severe PTSD had significant symptom reduction, and 67% were essentially cured.

  • What is John Lebecki's current status regarding PTSD after participating in the MDMA trial?

    -John Lebecki no longer clinically qualifies as having PTSD and has been healed for longer than he actually had PTSD.

  • What other psychedelic substances are being studied for mental health treatment in the script?

    -The script mentions that LSD is being studied for generalized anxiety disorder at the Cleveland Clinic, and a drug found in magic mushrooms is being studied at Ohio State University for helping veterans battling PTSD.

  • What is the current status of availability for these psychedelic treatments, and what are the challenges?

    -The treatments are not readily available yet due to a lack of trained providers to administer the drugs and navigate patient reactions.

  • What is John Lebecki's current advocacy work?

    -John Lebecki is advocating for veteran access to psychedelics and is also helping civilians in war-torn Ukraine, where he provides education on the topic.

Outlines

plate

Cette section est réservée aux utilisateurs payants. Améliorez votre compte pour accéder à cette section.

Améliorer maintenant

Mindmap

plate

Cette section est réservée aux utilisateurs payants. Améliorez votre compte pour accéder à cette section.

Améliorer maintenant

Keywords

plate

Cette section est réservée aux utilisateurs payants. Améliorez votre compte pour accéder à cette section.

Améliorer maintenant

Highlights

plate

Cette section est réservée aux utilisateurs payants. Améliorez votre compte pour accéder à cette section.

Améliorer maintenant

Transcripts

plate

Cette section est réservée aux utilisateurs payants. Améliorez votre compte pour accéder à cette section.

Améliorer maintenant
Rate This
★
★
★
★
★

5.0 / 5 (0 votes)

Étiquettes Connexes
PTSDVeteranMDMATherapySuicideClinical TrialsPsychedelicsMental HealthFDA ApprovalHope
Besoin d'un résumé en anglais ?